HMGB1 and neoplasm: Anti-TLR4 (Fig. 4A–h) and anti-RAGE pretreated tumor cells (Fig. 4A–i), however, lost the protective ability of HMGB1, as compared to HMGB1-treated tumor cells with control IgG (Fig. 4A–g).